Needham analyst Michael Matson has maintained their neutral stance on PEN stock, giving a Hold rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Matson’s rating is based on a combination of positive and cautious factors surrounding Penumbra’s financial performance and future prospects. The company reported better-than-expected revenue and earnings per share for the fourth quarter of 2024, with thrombectomy growth showing improvement and stable performance in embolization and access segments. Additionally, Penumbra achieved notable improvements in both gross and operating margins during this period.
However, the outlook for 2025 appears conservative, with projected revenue slightly below market expectations. Moreover, the upcoming launch of the Thunderbolt product, which holds potential as a significant growth catalyst, lacks a clear timeline, adding an element of uncertainty. Considering these aspects, including the company’s current valuation, Matson has opted to maintain a Hold rating on the stock.
According to TipRanks, Matson is an analyst with an average return of -4.8% and a 40.36% success rate. Matson covers the Healthcare sector, focusing on stocks such as Hologic, TransMedics Group, and Atricure.
In another report released today, Morgan Stanley also maintained a Hold rating on the stock with a $260.00 price target.